Compare Novavax Inc (NVAX) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Teucrium Soybean Fund — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while Teucrium Soybean Fund trades at $25.33. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SOYB | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $11.19 | $26.28 |
52-Week Low | $6.22 | $21.46 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
SOYB trades at $25.24, up 0.28% on the day, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights agricultural sector tailwinds from China's crop purchase pledge, though geopolitical risks from Middle East tensions pose headwinds.
The outlook hinges on sector-specific catalysts like export demand, but absent financial data obscures valuation. Risks include commodity volatility and geopolitical spillovers. Investors require updated SEC filings to assess profitability and growth prospects amid mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
